Joel Isaacson & Co. LLC Has $507,000 Stock Position in Stryker Corporation $SYK

Joel Isaacson & Co. LLC trimmed its holdings in shares of Stryker Corporation (NYSE:SYK) by 9.1% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 1,282 shares of the medical technology company’s stock after selling 129 shares during the period. Joel Isaacson & Co. LLC’s holdings in Stryker were worth $507,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Mogy Joel R Investment Counsel Inc. increased its position in Stryker by 3.4% in the 1st quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company’s stock worth $36,561,000 after purchasing an additional 3,218 shares during the last quarter. Ferguson Wellman Capital Management Inc. increased its position in Stryker by 1.9% in the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company’s stock worth $65,096,000 after purchasing an additional 3,341 shares during the last quarter. Harbor Capital Advisors Inc. acquired a new position in Stryker in the 1st quarter worth about $1,840,000. Mar Vista Investment Partners LLC increased its position in Stryker by 10.2% in the 1st quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock worth $33,572,000 after purchasing an additional 8,353 shares during the last quarter. Finally, United Services Automobile Association acquired a new position in Stryker in the 1st quarter worth about $2,857,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Performance

SYK opened at $369.14 on Wednesday. The firm has a market capitalization of $141.12 billion, a P/E ratio of 48.89, a price-to-earnings-growth ratio of 2.64 and a beta of 0.94. The stock’s 50 day moving average price is $381.50 and its two-hundred day moving average price is $378.86. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company’s revenue was up 11.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, equities analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is currently 44.50%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Needham & Company LLC increased their price objective on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a report on Friday, August 1st. Rothschild Redb raised Stryker to a “hold” rating in a report on Thursday, September 18th. Evercore ISI lowered their price objective on Stryker from $418.00 to $410.00 and set an “outperform” rating on the stock in a report on Tuesday. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a report on Friday, September 26th. Finally, Redburn Partners set a $420.00 price objective on Stryker in a report on Thursday, September 18th. Fifteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $430.10.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.